Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 15, 2026, 7:52 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 59 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Transplantation, Cornea Clear all
Completed No phase listed Observational

A Retrospective Review of DEXTENZA 0.4 mg inseRt Following Corneal Transplant or Cataract Surgery

NCT04975971
View directory record Official record
Conditions
Anterior Chamber Inflammation, Ocular Pain, Corneal Edema, Corneal Defect, Penetrating KeratoPlasty, Nuclear Cataract, Cortical Cataract, Cataract Senile
Interventions
Dextenza 0.4Mg Ophthalmic Insert
Drug
Lead sponsor
Nicole Fram M.D.
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 25, 2021 · Synced Sep 15, 2026, 7:52 PM EDT
Terminated Phase 3 Interventional

Study to Assess the Efficacy and Safety of LX201 for Prevention of Corneal Allograft Rejection Episodes and Graft Failure in Subjects at Increased Immunological Risk

NCT00447187
View directory record Official record
Conditions
Corneal Diseases, Cornea Transplant
Interventions
LX201, Placebo
Drug · Other
Lead sponsor
Lux Biosciences, Inc.
Industry
Eligibility
18 Years and older
Enrollment
368 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
24
States / cities
Phoenix, Arizona • Loma Linda, California • Los Angeles, California + 19 more
Source: ClinicalTrials.gov public record
Updated Oct 10, 2012 · Synced Sep 15, 2026, 7:52 PM EDT
Withdrawn Phase 1 Interventional

Subconjunctival IVIg (Gamunex-C) Injection for Corneal Neovascularization and Inflammatory Conditions

NCT02042027
View directory record Official record
Conditions
Corneal Neovascularization, Corneal Graft Failure, Anterior Segment Inflammation
Interventions
Gamunex-C
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Aug 4, 2016 · Synced Sep 15, 2026, 7:52 PM EDT
Recruiting Phase 4 Interventional

Glanatec(R) for Descemet Stripping in Fuch's Endothelial Dystrophy

NCT03249337
View directory record Official record
Conditions
Fuchs' Endothelial Dystrophy
Interventions
Ripasudil hydrochloride hydrate 0.4% ophthalmic solution
Drug
Lead sponsor
Marian Macsai, MD
Other
Eligibility
18 Years to 91 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Glenview, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 10, 2021 · Synced Sep 15, 2026, 7:52 PM EDT
Terminated Phase 3 Interventional

Study to Assess LX201 for Prevention of Corneal Allograft Rejection or Graft Failure in Subjects Who Have Experienced One or More Rejection Episodes Following Penetrating Keratoplasty

NCT00447642
View directory record Official record
Conditions
Corneal Transplantation, Corneal Graft Rejection
Interventions
LX201, Placebo
Drug · Other
Lead sponsor
Lux Biosciences, Inc.
Industry
Eligibility
18 Years and older
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
24
States / cities
Phoenix, Arizona • Loma Linda, California • Los Angeles, California + 19 more
Source: ClinicalTrials.gov public record
Updated Oct 10, 2012 · Synced Sep 15, 2026, 7:52 PM EDT
Not yet recruiting Not applicable Interventional

A Randomized Clinical Trial of Ex Vivo Corneal Cross-Linking of Donor Keratoplasty Tissue for Keratoconus Used for Keratoplasty in Keratoconus Patients

NCT04584125
View directory record Official record
Conditions
Keratoconus
Interventions
Riboflavin 5'-phosphate in 20% dextran ophthalmic solution) 0.146% with UV light, Riboflavin 5'-phosphate in 20% dextran ophthalmic solution) 0.146% without UV light
Drug
Lead sponsor
Joseph B. Ciolino, MD
Other
Eligibility
18 Years to 50 Years
Enrollment
216 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2028
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 7, 2026 · Synced Sep 15, 2026, 7:52 PM EDT
Terminated No phase listed Observational

Descemet Membrane Endothelial Keratoplasty vs. Descemet's Stripping With Endothelial Keratoplasty vs. Descemet Stripping Only

NCT04527523
View directory record Official record
Conditions
Cystoid Macular Edema, Fuchs Dystrophy
Interventions
Optical Coherence Tomography
Diagnostic Test
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 12, 2023 · Synced Sep 15, 2026, 7:52 PM EDT
Recruiting Phase 2 Interventional

Targeting Reactive Oxygen Species Production as a Novel Therapeutic in Fuch's Endothelial Corneal Dystrophy

NCT04440280
View directory record Official record
Conditions
Fuchs Endothelial Corneal Dystrophy
Interventions
N-acetyl cysteine (NAC) 10% solution, N-acetyl cysteine (NAC) 20% solution, Visine Dry Eye Relief eye drops
Drug
Lead sponsor
Massachusetts Eye and Ear Infirmary
Other
Eligibility
21 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Sep 15, 2026, 7:52 PM EDT
Completed Not applicable Interventional Results available

Study of Eye Bank Pre-cut Donor Grafts for Endothelial Keratoplasty

NCT00624221
View directory record Official record
Conditions
Fuchs Endothelial Dystrophy, Corneal Edema
Interventions
Descemet's stripping endothelial keratoplasty
Procedure
Lead sponsor
Cornea Research Foundation of America
Other
Eligibility
21 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Apr 26, 2016 · Synced Sep 15, 2026, 7:52 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Safety and Efficacy of Bevacizumab in High-Risk Corneal Transplant Survival

NCT01072357
View directory record Official record
Conditions
Corneal Neovascularization, Corneal Graft Failure
Interventions
Avastin® (bevacizumab), 0.9% NaCl & Refresh Liquigel
Drug
Lead sponsor
Reza Dana, MD
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 14, 2018 · Synced Sep 15, 2026, 7:52 PM EDT
Completed Phase 1Phase 2 Interventional Results available

A Multi-Center Study of the Safety and Efficacy of Bevacizumab in High-Risk Corneal Transplant Survival

NCT01996826
View directory record Official record
Conditions
Corneal Neovascularization, Corneal Graft Failure
Interventions
Avastin® (bevacizumab), 0.9% NaCl & Refresh Liquigel
Drug
Lead sponsor
Reza Dana, MD
Other
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
3
States / cities
Miami, Florida • Boston, Massachusetts • New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 9, 2020 · Synced Sep 15, 2026, 7:52 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Limbal Stem Cell Deficiency (LSCD) Treatment With Cultivated Stem Cell (CALEC) Graft

NCT02592330
View directory record Official record
Conditions
Limbal Stem Cell Deficiency
Interventions
Biopsy to collect limbal epithelial stem cells that will be cultivated into a graft, Cultivation of Limbal epithelial cells into a graft, CALEC Transplant
Procedure · Biological
Lead sponsor
Massachusetts Eye and Ear Infirmary
Other
Eligibility
18 Years to 89 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 14, 2025 · Synced Sep 15, 2026, 7:52 PM EDT
Completed Phase 4 Interventional

Assessing eFficacy and Safety of DEXTENZA 0.4 mg inseRt, Following Corneal Transplant Surgery

NCT04521140
View directory record Official record
Conditions
Corneal Edema, Corneal Defect, Corneal Transplant, Penetrating KeratoPlasty, Anterior Chamber Inflammation, Ocular Pain, Intraocular Pressure
Interventions
Dextenza 0.4Mg Ophthalmic Insert, Prednisolone Acetate 1% Oph Susp
Drug
Lead sponsor
Nicole Fram M.D.
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 23, 2023 · Synced Sep 15, 2026, 7:52 PM EDT
Not listed Phase 4 Interventional Results available

Descemet Endothelial Thickness Comparison Trial

NCT02373137
View directory record Official record
Conditions
Keratoplasty, Grafting, Corneal, Transplantation, Corneal, Transplantation, Cornea, Keratoplasty, Lamellar
Interventions
DSAEK, DMEK, Endoserter, Prednisolone, Ofloxacin, Tropicamide, Phenylephrine, Jones Tube
Procedure · Device · Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2023
U.S. locations
3
States / cities
Palo Alto, California • San Francisco, California • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Nov 24, 2020 · Synced Sep 15, 2026, 7:52 PM EDT
Recruiting Phase 2 Interventional

DT-168 in Keratoplasty Patients With Fuchs Endothelial Corneal Dystrophy

NCT07024693
View directory record Official record
Conditions
Fuchs Endothelial Corneal Dystrophy, Fuchs
Interventions
DT-168
Drug
Lead sponsor
Design Therapeutics, Inc.
Industry
Eligibility
30 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
2
States / cities
Indianapolis, Indiana • Grand Rapids, Michigan
Source: ClinicalTrials.gov public record
Updated Dec 28, 2025 · Synced Sep 15, 2026, 7:52 PM EDT
Not yet recruiting Phase 4 Interventional

Outcomes of CTAK Surgery

NCT07474870
View directory record Official record
Conditions
Keratoconus, Corneal Ectasia
Interventions
Questionnaire and Physical Exam
Behavioral
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 85 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Apr 23, 2026 · Synced Sep 15, 2026, 7:52 PM EDT
Recruiting Phase 2 Interventional

ExCrossV Multi Site Trial for Vascularized High Risk Keratoplasty

NCT06753916
View directory record Official record
Conditions
Corneal Transplant Failure
Interventions
Corneal Donor Tissue with Cross Linking, Corneal Donor Tissue without Cross Linking
Procedure
Lead sponsor
Massachusetts Eye and Ear Infirmary
Other
Eligibility
18 Years and older
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
12
States / cities
Irvine, California • Los Angeles, California • San Francisco, California + 9 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced Sep 15, 2026, 7:52 PM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

Early Experience With Descemet's Stripping Automated Endothelial Keratoplasty

NCT00744796
View directory record Official record
Conditions
Corneal Edema Secondary to Corneal Endothelial Dystrophy
Interventions
DSAEK, Anterior Segment Optical Coherence Topography (OCT), Best Spectacle Corrected Visual Acuity (BSCVA)
Procedure · Diagnostic Test
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2009
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Dec 10, 2020 · Synced Sep 15, 2026, 7:52 PM EDT
Recruiting Not applicable Interventional

Plasma Rich in Growth Factors in Corneal Endothelial Transplantation

NCT06261346
View directory record Official record
Conditions
Fuchs' Endothelial Dystrophy, Corneal Edema
Interventions
Endothelial keratoplasty, PRGF
Procedure · Biological
Lead sponsor
University of Miami
Other
Eligibility
18 Years to 80 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
2
States / cities
Miami, Florida • Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Apr 8, 2026 · Synced Sep 15, 2026, 7:52 PM EDT
Enrolling by invitation Not applicable Interventional

Effect of Donor Diabetes and Other Factors on Corneal Transplant Endothelial Cell Loss and Success at 5 Years

NCT07217249
View directory record Official record
Conditions
Fuchs Endothelial Corneal Dystrophy, Corneal Endothelial Decompensation
Interventions
Descemet membrane endothelial keratoplasty
Procedure
Lead sponsor
Case Western Reserve University
Other
Eligibility
30 Years to 93 Years
Enrollment
570 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
14
States / cities
Atlanta, Georgia • Indianapolis, Indiana • Iowa City, Iowa + 10 more
Source: ClinicalTrials.gov public record
Updated Feb 26, 2026 · Synced Sep 15, 2026, 7:52 PM EDT
Terminated Not applicable Interventional

OCT-guided LALAK in Children

NCT01579643
View directory record Official record
Conditions
Corneal Opacity
Interventions
OCT guided laser-assisted lamellar anterior keratoplasty (LALAK), Penetrating Keratoplasty (KP)
Procedure
Lead sponsor
Oregon Health and Science University
Other
Eligibility
1 Month to 18 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 16, 2018 · Synced Sep 15, 2026, 7:52 PM EDT
Completed Not applicable Interventional

Femtosecond Laser Assisted Keratoplasty

NCT00802776
View directory record Official record
Conditions
Keratoconus
Interventions
Femtosecond laser assisted keratoplasty, PKP
Procedure
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 60 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2016
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 14, 2017 · Synced Sep 15, 2026, 7:52 PM EDT
Withdrawn No phase listed Observational Accepts healthy volunteers

Deep Lamellar Endothelial Keratoplasty: Small Incision Technique

NCT00345020
View directory record Official record
Conditions
Corneal Transplantation
Interventions
Deep Lamellar Endothelial Keratoplasty: Small Incision Technique
Procedure
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
21 Years to 95 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2006
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Aug 14, 2018 · Synced Sep 15, 2026, 7:52 PM EDT
Completed Not applicable Interventional

A Comparison Between Full Thickness and Partial Thickness Corneal Transplantation for Corneal Edema

NCT00346138
View directory record Official record
Conditions
Fuchs Dystrophy, Corneal Edema
Interventions
Corneal transplantation
Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
21 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 14, 2010 · Synced Sep 15, 2026, 7:52 PM EDT